GSK, WHO, Partners To Begin Pilot Program For RTS,S Malaria Vaccine In 3 African Countries

STAT: A pivotal test of an experimental malaria vaccine set to begin
“Researchers are preparing to launch a pivotal test of an experimental malaria vaccine this month — one that global health leaders believe could eventually lead to big reductions in the number of cases and deaths worldwide. Despite those high hopes, there are also concerns that the theoretical benefits of the vaccine, made by GSK, might not translate into the real world. To see whether the vaccine lives up to its promise, the World Health Organization and partners have designed a sort of beta rollout of the vaccine, called RTS,S…” (Branswell, 4/19).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.